View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Bibliography 264 Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepat. 2006 Feb;13(2):96- 103. 76. de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/ tenofovir therapy in HIV-HBV co-infected patients. J Clin Virol. 2006 May;36(1):60-3. Epub 2006 Jan 18. 77. van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, Schalm SW. Generic and disease-specifi c health related quality of life of liver patients with various aetiologies: A survey. Qual Life Res. 2007 Apr;16(3):375-88. Epub 2006 Nov 25. 78. Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology. 2007 Jan;45(1):258-9. 79. Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL; HBV 99-01 Study Group. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006 Nov;101(11):2523-9. 80. Sprengers D, van der Molen RG, Kusters JG, Hansen B, Niesters HG, Schalm SW, Janssen HL. Different composition of intrahepatic lymphocytes in the immune-tolerance and immuneclearance phase of chronic hepatitis B. J Med Virol. 2006 May;78(5):561-8. 81. Tapirdamaz O, Pravica V, Metselaar HJ, Hansen B, Moons L, van Meurs JB, Hutchinson IV, Shaw J, Agarwal K, Adams DH, Day CP, Kwekkeboom J. Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 infl uence the rate of acute rejection after liver transplantation.Gut. 2006 Jun;55(6):863-8. 82. de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, Kuipers EJ. Epidemiological trends of pre-malignant gastric lesions; a long-term nationwide study in the Netherlands. Gut. 2007 Dec;56(12):1665-70. Gut. 2007 Aug 14; [Epub ahead of print] 83. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Vand der Woude CJ. Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of infl ammatory bowel disease. Aliment Pharmacol Ther. 2007 Sep 1;26(5):643-52. 84. Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fi brosis. Hepatology. 2007 Aug;46(2):388-94. 85. Hou J, Schilling R, Janssen HL, Hansen BE, Heijtink R, Sablon E, Williams R, Lau GK, Schalm SW, Naoumov NV.
Bibliography 265 Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol. 2007 Aug;79(8):1055-63. 86. Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys Veer A, de Vries RA, Verhey E, Hansen BE, Brouwer JT, Janssen HL, Schalm SW, de Knegt RJ. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int. 2007 Nov;27(9):1217-25. PMID: 17919233 87. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.Gastroenterology. 2008 Aug;135(2):459-67. Epub 2008 May 15. PMID: 18585385 88. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008 Jun;47(6):1856-62. PMID: 18506898 89. ter Borg MJ, Hansen BE, Bigot G, Haagmans BL, Janssen HL. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol. 2008 Jun;42(2):160-4. Epub 2008 Mar 24. PMID: 18359663 90. Murad SD, Luong TK, Pattynama PM, Hansen BE, van Buuren HR, Janssen HL. Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. Liver Int. 2008 Feb;28(2):249-56. PMID: 18251982 91. ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van’ t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL; HBV 99-01 Study Group. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. Antivir Ther. 2007;12(8):1285-94. PMID: 18240868 92. Spaander MC, Murad SD, van Buuren HR, Hansen BE, Kuipers EJ, Janssen HL. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc. 2008 May;67(6):821-7. Epub 2008 Jan 18. PMID: 18206153 93. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, van der Ende ME. A prospective open study of the effi cacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. Infect Dis. 2008 Jan 15;197(2):292-4. PMID: 18177248 94. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fi brosis.Ann Intern Med. 2007 Nov 20;147(10):677-84. Summary for patients in: Ann Intern Med. 2007 Nov 20;147(10):I47.PMID: 18025443 95. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that Predict Response of Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144:
Cha pter 3.2 Discriminant analysis
Page 145 and 146:
Introduction Discriminant analysis
Page 147 and 148:
Discriminant analysis using a MLMM
Page 149 and 150:
Estimation Discriminant analysis us
Page 151 and 152:
Page 153 and 154:
where wi,k(y i, θ) = (k =1,...,K).
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Appendix Discriminant analysis usin
Page 175:
Cha pter 4 Statistical models of ea
Page 178 and 179:
Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181:
Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183:
Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185:
Chapter 4.1 182 Figure 1.
Page 186 and 187:
Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189:
Chapter 4.1 186 suppression in seru
Page 190 and 191:
Chapter 4.1 188 13. Seifer M, Hamat
Page 193 and 194:
Cha pter 4.2 Viral dynamics during
Page 195 and 196:
INTRODUCTION Viral dynamics during
Page 197 and 198:
Viral dynamics during tenofovir the
Page 199 and 200:
Page 201 and 202:
log HBV DNA (copies/mL) 10.0 9.0 8.
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 211 and 212:
Chap ter 4.3 Modelling of early vir
Page 213 and 214:
INTRODUCTION HBV viral kinetics dur
Page 215 and 216: HBV viral kinetics during PEG-IFN 2
Page 229: HBV viral kinetics during PEG-IFN 2
Page 233 and 234: SUMMARY AND CONCLUSION Summary and
Page 235 and 236: Summary and conclusion 233 The mode
Page 237 and 238: Summary and conclusion 235 The infe
Page 239: Summary and conclusion 237 Early st
Page 243 and 244: SAMENVATTING EN CONCLUSIE Samenvatt
Page 245 and 246: Samenvatting en conclusie 243 Er we
Page 247 and 248: Samenvatting en conclusie 245 Data
Page 249 and 250: Samenvatting en conclusie 247 Behan
Page 253: Dan kwoord
Page 256 and 257: Dankwoord 254 Lieve Marion en Margr
Page 259 and 260: BIBLI OGRAPHY Bibliography 257 1. K
Page 261 and 262: Bibliography 259 Interferon-ribavir
Page 263 and 264: Bibliography 261 Long term clinical
Page 265: Bibliography 263 Flares in chronic
Page 269: Bibliography 267 106. Reijnders JG,
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

Create successful ePaper yourself

Delete template?

Save as template?